Welcome to our dedicated page for BioAtla news (Ticker: BCAB), a resource for investors and traders seeking the latest updates and insights on BioAtla stock.
BioAtla, Inc. (NASDAQ: BCAB) is a clinical-stage biopharmaceutical company committed to advancing the treatment of cancer through its innovative protein therapeutic products. Headquartered in San Diego, California, with a strategic presence in Beijing, China, BioAtla leverages its proprietary Conditionally Active Biologics (CAB) technology to develop novel monoclonal and bispecific antibodies.
The core of BioAtla's work lies in the engineering of antibodies that become active under the unique conditions of the tumor microenvironment, thus improving tumor selectivity and reducing on-target toxicity. This technology aims to enhance the therapeutic index of drug candidates, ultimately providing safer and more effective cancer treatments.
BioAtla's pipeline includes several promising candidates. Mecbotamab vedotin (BA3011) and ozuriftamab vedotin (BA3021) are in Phase 2 clinical testing, targeting AXL and ROR2 respectively. Another key asset, evalstotug (BA3071), is a CTLA-4 inhibitor designed to minimize systemic toxicity and facilitate safer combination therapies with anti-PD-1 antibodies. Furthermore, the company's first bispecific T-cell engager antibody, BA3182, is undergoing Phase 1 trials, focusing on EpCAM and engaging CD3 expressing T cells.
BioAtla has an extensive patent portfolio, with over 750 patents filed, more than 475 of which have been granted. This robust intellectual property coverage supports the company's competitive edge in the biotechnology sector.
Recent updates include the initiation of a Phase 1 clinical trial for BA3361, a next-generation CAB-Nectin4-ADC, which demonstrated superior activity in pancreatic cancer models. The company also continues to build strategic partnerships and collaborations to advance its research and commercialize its products effectively.
For further information and the latest updates, visit BioAtla's official website or contact their investor relations team.
BioAtla, Inc. (Nasdaq: BCAB) will host a conference call and webcast on May 14, 2024, at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2024, and provide business highlights. The company focuses on developing CAB antibody therapeutics for solid tumors.
BioAtla, Inc. (Nasdaq: BCAB) received FDA clearance for its investigational new drug BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for treating various tumors. The CAB technology aims to reduce toxicities, and recent data at the AACR Annual Meeting showcased improved serum stability and potency. BA3361 showed complete tumor regression in cell line xenograft models, superior efficacy in pancreatic cancer, and reduced toxicity. This marks BioAtla's advancement in developing innovative cancer treatments.
FAQ
What is the current stock price of BioAtla (BCAB)?
What is the market cap of BioAtla (BCAB)?
What is BioAtla, Inc. known for?
Where are BioAtla's main operations located?
What are BioAtla's leading drug candidates?
What is CAB technology?
How extensive is BioAtla's patent portfolio?
What recent developments has BioAtla announced?
Who can I contact for more information about BioAtla?
What types of cancers are BioAtla's treatments targeting?
What are the benefits of BioAtla's CAB technology?
Where can I find BioAtla's latest news and updates?
